EU approves Novartis glaucoma combo

30th July 2014

Patients with glaucoma in Europe can now get access to Novartis’ Simbrinza (brinzolamide/brimonidine tartrate), the only fixed-combination therapy that doesn’t involve a beta-blocker.

The European Commission has approved the eye drops to decrease elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension, for which monotherapy provides insufficient IOP reduction.

Read more at source article: www.pharmatimes.com


Leave a Reply

Your email address will not be published.

− 2 = 2

« back to posts